• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

同源 Spikevax 或异源 Vaxzevria-Spikevax 疫苗接种后对 SARS-CoV-2 Delta 变异株诱导产生中和抗体的效果显著。

Robust induction of neutralizing antibodies against the SARS-CoV-2 Delta variant after homologous Spikevax or heterologous Vaxzevria-Spikevax vaccination.

机构信息

Hannover Medical School, Institute of Immunology, Hannover, Germany.

Institute of Molecular and Clinical Immunology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany.

出版信息

Eur J Immunol. 2022 Feb;52(2):356-359. doi: 10.1002/eji.202149645. Epub 2022 Jan 7.

DOI:10.1002/eji.202149645
PMID:34870322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9015245/
Abstract

Sera of vaccines were assessed by surrogate virus neutralization tests for their capacity to neutralize the SARS-CoV-2 Delta variant. Homologous prime-boost immunization with Moderna's Spikevax as well as heterologous immunization with AstraZeneca's Vaxzevria followed by Moderna's Spikevax were identified as highly potent vaccination regimens for the induction of Delta-neutralizing antibodies.

摘要

疫苗血清通过替代病毒中和试验评估其中和 SARS-CoV-2 德尔塔变异株的能力。使用 Moderna 的 Spikevax 进行同源加强免疫以及使用 AstraZeneca 的 Vaxzevria 进行异源免疫后再使用 Moderna 的 Spikevax 被鉴定为诱导德尔塔中和抗体的高效疫苗接种方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b96/9015245/4c6e8dc53e69/EJI-52--g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b96/9015245/5a677c90291a/EJI-52--g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b96/9015245/4c6e8dc53e69/EJI-52--g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b96/9015245/5a677c90291a/EJI-52--g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b96/9015245/4c6e8dc53e69/EJI-52--g001.jpg

相似文献

1
Robust induction of neutralizing antibodies against the SARS-CoV-2 Delta variant after homologous Spikevax or heterologous Vaxzevria-Spikevax vaccination.同源 Spikevax 或异源 Vaxzevria-Spikevax 疫苗接种后对 SARS-CoV-2 Delta 变异株诱导产生中和抗体的效果显著。
Eur J Immunol. 2022 Feb;52(2):356-359. doi: 10.1002/eji.202149645. Epub 2022 Jan 7.
2
Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.奥密克戎变异株对疫苗加强后免疫血清的中和敏感性低于其他 SARS-CoV-2 变异株。
Emerg Microbes Infect. 2022 Dec;11(1):337-343. doi: 10.1080/22221751.2021.2022440.
3
Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.接种 SARS-CoV-2 疫苗或感染一年后均可检测到强大的中和抗体水平。
Viruses. 2021 Oct 5;13(10):2003. doi: 10.3390/v13102003.
4
CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant.科兴和国药疫苗接种和伽马感染诱导针对 SARS-CoV-2 德尔塔变异株的中和抗体。
Viruses. 2022 Feb 1;14(2):305. doi: 10.3390/v14020305.
5
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.
6
Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.评估针对 SARS-CoV-2 的 IgG 和中和抗体的免疫原性检测方法的稳健验证和性能比较。
PLoS One. 2022 Feb 7;17(2):e0262922. doi: 10.1371/journal.pone.0262922. eCollection 2022.
7
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.mRNA-1273 对 SARS-CoV-2 变异株的血清中和活性。
J Virol. 2021 Nov 9;95(23):e0131321. doi: 10.1128/JVI.01313-21. Epub 2021 Sep 22.
8
Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.既往感染与疫苗接种产生针对 SARS-CoV-2 变异株的中和抗体效力。
mBio. 2021 Dec 21;12(6):e0265621. doi: 10.1128/mBio.02656-21. Epub 2021 Dec 7.
9
Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.CoronaVac 疫苗诱导的抗体对 alpha、gamma 和 D614G SARS-CoV-2 变异株的中和作用。
J Med Virol. 2022 Jan;94(1):399-403. doi: 10.1002/jmv.27310. Epub 2021 Sep 8.
10
Limited Impact of Delta Variant's Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population.在拉丁裔人群中，德尔塔变异株的突变对自然感染或 COVID-19 疫苗所赋予的中和效果的影响有限。
Viruses. 2021 Nov 30;13(12):2405. doi: 10.3390/v13122405.

引用本文的文献

1
Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape.临床视角下的纳米颗粒疗法：分类、上市产品及监管格局
Small. 2025 Jun 2:e2502315. doi: 10.1002/smll.202502315.
2
Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy.优化吸入型 LNP 制剂用于通过 mRNA 介导的抗体疗法增强特发性肺纤维化的治疗。
Nat Commun. 2024 Aug 10;15(1):6844. doi: 10.1038/s41467-024-51056-8.
3
An assessment of the strategy and status of COVID-19 vaccination in India.

本文引用的文献

1
Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination.异源和同源接种BNT162b2或ChAdOx1 nCoV-19疫苗后对严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）德尔塔变异株的中和作用。
Cell Mol Immunol. 2021 Oct;18(10):2455-2456. doi: 10.1038/s41423-021-00755-z. Epub 2021 Aug 23.
2
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.异源 ChAdOx1 nCoV-19/mRNA 疫苗接种的免疫原性和反应原性。
Nat Med. 2021 Sep;27(9):1530-1535. doi: 10.1038/s41591-021-01464-w. Epub 2021 Jul 26.
3
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
印度 COVID-19 疫苗接种策略和现状评估。
Immunol Res. 2023 Aug;71(4):565-577. doi: 10.1007/s12026-023-09373-5. Epub 2023 Apr 11.
4
Circular RNAs as emerging regulators in COVID-19 pathogenesis and progression.环状 RNA 作为 COVID-19 发病机制和进展中的新兴调节因子。
Front Immunol. 2022 Nov 9;13:980231. doi: 10.3389/fimmu.2022.980231. eCollection 2022.
5
Recent review of COVID-19 management: diagnosis, treatment and vaccination.近期对 COVID-19 管理的回顾：诊断、治疗和疫苗接种。
Pharmacol Rep. 2022 Dec;74(6):1120-1148. doi: 10.1007/s43440-022-00425-5. Epub 2022 Oct 10.
6
RNA Viruses, Pregnancy and Vaccination: Emerging Lessons from COVID-19 and Ebola Virus Disease.RNA病毒、妊娠与疫苗接种：来自新冠病毒病和埃博拉病毒病的新经验教训
Pathogens. 2022 Jul 15;11(7):800. doi: 10.3390/pathogens11070800.
7
Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review.腺病毒载体疫苗和 mRNA COVID-19 疫苗异源与同源加强免疫接种程序的免疫原性和安全性：系统评价。
Infect Dis Poverty. 2022 May 13;11(1):53. doi: 10.1186/s40249-022-00977-x.
8
Augmented neutralization of SARS-CoV-2 Omicron variant by boost vaccination and monoclonal antibodies.加强针接种和单克隆抗体对 SARS-CoV-2 奥密克戎变异株的中和增强作用。
Eur J Immunol. 2022 Jun;52(6):970-977. doi: 10.1002/eji.202249841. Epub 2022 Mar 23.
Covid-19 疫苗对 B.1.617.2（德尔塔）变异株的有效性。
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.
4
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.接种 ChAdOx1 nCoV-19/BNT162b2 异源和同源疫苗后针对 SARS-CoV-2 变体的免疫反应。
Nat Med. 2021 Sep;27(9):1525-1529. doi: 10.1038/s41591-021-01449-9. Epub 2021 Jul 14.
5
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.异源ChAdOx1 nCoV-19疫苗和mRNA-1273疫苗接种
N Engl J Med. 2021 Sep 9;385(11):1049-1051. doi: 10.1056/NEJMc2110716. Epub 2021 Jul 14.
6
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.德尔塔变异株对抗体中和的敏感性降低。
Nature. 2021 Aug;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8.
7
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.BNT162b2 加强剂在 ChAdOx1-S 初免参与者中的免疫原性和反应原性（CombiVacS）：一项多中心、开放标签、随机、对照、2 期临床试验。
Lancet. 2021 Jul 10;398(10295):121-130. doi: 10.1016/S0140-6736(21)01420-3. Epub 2021 Jun 25.
8
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.苏格兰的新冠病毒德尔塔变异株：人口统计学、住院风险及疫苗有效性
Lancet. 2021 Jun 26;397(10293):2461-2462. doi: 10.1016/S0140-6736(21)01358-1. Epub 2021 Jun 14.